Spero Therapeutics, Inc. — Form 8-K
Filed July 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Spero acquired exclusive global rights (ex-Greater China) to SP001 (IBI355), a Phase 2-ready anti-CD40L antibody from Innovent Biologics. Deal structure: Innovent receives upfront payment plus development, regulatory, and commercial milestones totaling ~$1.1B, plus tiered royalties on net sales. Concurrently, Spero secured $105M non-recourse financing from Healthcare Royalty (KKR affiliate) backed by Utebzi milestone/royalty streams. Cash runway extended to 2H 2029. Phase 2 trial in IgG4-RD planned for Q2 2027.
Why this rating
Two transformational deals significantly expand pipeline (immunology pivot) and extend runway. Combined deal value (~$1.1B+ $105M) large relative to $160M market cap; extends cash 3+ years. High risk but strategically repositioning company.
See more from July 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.